From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
  •  ?
Routes of
Legal status
Legal status
Pharmacokinetic data
Biological half-life 16 hours[1]
CAS Number 2240-14-4
ATC code N06BA06 (WHO)
PubChem CID 14584
DrugBank DB01463
ChemSpider 13922
Chemical data
Formula C15H21N
Molar mass 215.33 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dextroamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still used, though rarely, for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases.[2]

Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is ten times less potent than dexamphetamine at producing this effect. The main mechanism of action is instead inhibition of dopamine reuptake, more similar to that of methylphenidate. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer.[3] Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.[4]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Delbeke FT, Debackere M (1981). "Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion". Biopharmaceutics & Drug Disposition. 2 (1): 17–30. doi:10.1002/bdd.2510020103. PMID 7236868. 
  3. Seyfried, CA (1983). "Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study". Biochemical pharmacology. 32 (15): 2329–31. doi:10.1016/0006-2952(83)90181-8. PMID 6136281.  edit
  4. Planeta Cda, S; Aizenstein, ML; Delucia, R (1995). "Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors". Pharmacology, biochemistry, and behavior. 50 (1): 35–40. doi:10.1016/0091-3057(94)00236-C. PMID 7700952.  edit